The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Our mission is to accelerate the clinical development of immune tolerance therapies in asthma and allergy, autoimmune diseases, type 1 diabetes and solid organ transplantation. Immune tolerance therapies reprogram the immune system so that disease-causing immune responses are stopped while maintaining the immune system's ability to combat pathogen infection. The ITN develops, funds and conducts clinical trials in conjunction with mechanistic, laboratory based studies.